NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Collaborate to Develop and Commercialise NRX-101
Monday, June 05, 2023
Lotus Pharmaceuticals, Alvogen and NRx Pharmaceuticals have entered into a global collaboration agreement.
Under the terms of the agreement, relating to NRX-101 for the U.S. market, NRx is entitled to receive an initial payment of $10 million upon achieving both a successful read-out from the ongoing Phase 2b/3 clinical trial in S-TRB and completion of a Type B meeting with the U.S. Food and Drug Administration (FDA).
The collaboration aims to develop and commercialise NRX-101 specifically for the treatment of suicidal treatment-resistant bipolar depression (S-TRBD) in global markets. Moreover, this collaboration aims to address the therapeutic needs of patients with suicidal treatment-resistant bipolar depression (S-TRBD), a condition for which effective treatment options are limited.
Under the collaboration agreement, Lotus Pharmaceuticals will acquire the global rights for NRX-101, specifically for the treatment of suicidal treatment-resistant bipolar depression (S-TRBD). They will leverage their direct commercial presence in certain Asian markets to promote and distribute NRX-101 to those in need.
NRX-101 is an innovative oral antidepressant currently undergoing late-stage clinical studies. It targets the NMDA receptor in the brain, which potentially provides a significant breakthrough in the treatment of depression, both with and without suicidality.
